Amanat pays AED105m for full control of 715-bed Cambridge Health Group

Amanat Holdings PJSC paid AED105 million for the final 10.03% of Cambridge Health Group, taking full control of a 715-bed post-acute care platform valued near AED1 billion.

The deal gives the Dubai-listed investor direct control of rehabilitation, long-term care and home healthcare capacity across the UAE and Saudi Arabia, a market where hospital discharge pressure, insurer cost control and chronic care needs are converging. For healthcare CEOs and CFOs, the number to remember is 1,000 beds: Amanat says Cambridge Health Group is targeting more than that level through organic growth, new developments and acquisitions.

What Amanat bought

Investors in Healthcare, citing Amanat, reported on 19 June 2026 that the acquisition completed a phased process that included a roughly 3% stake purchase earlier in June 2026. The final AED105 million payment bought the remaining 10.03% from minority shareholders and valued Cambridge Health Group at around AED1 billion.

“Full ownership allows us to move with greater speed and conviction behind a business that is already outperforming,” said John Ireland, chief executive officer of Amanat Holdings.

Cambridge Health Group operates six facilities across the UAE and Saudi Arabia, with more than 1,200 healthcare professionals, according to Investors in Healthcare. Its services include inpatient rehabilitation, long-term care, post-acute recovery, outpatient rehabilitation and home healthcare. The group holds JCI and CARF accreditations, which hospitals and payers often use when assessing referral partners.

The financial case

Cambridge Health Group reported AED404 million in revenue for FY2025, up 11% year on year, according to figures reported by Investors in Healthcare. EBITDA rose 14% to AED100 million. In Q1 2026, revenue grew 27%, EBITDA increased 49%, and profit rose six-fold year on year.

• AED105 million: price paid for the final 10.03% stake.
• AED1 billion: approximate valuation implied by the transaction.
• 715 beds: current Cambridge Health Group capacity across six facilities.
• 1,000+ beds: Amanat's medium-term target for Cambridge Health Group.

For CFOs, the transaction prices post-acute care as a scalable infrastructure asset. The AED1 billion valuation against AED100 million of FY2025 EBITDA puts occupancy, payer mix and clinical staffing at the centre of the investment case. Hospital groups without step-down capacity should watch discharge costs, referral leakage and negotiations with rehabilitation providers.

What healthcare operators should watch

In Abu Dhabi and Al Ain, Cambridge Health Group operates under the Department of Health Abu Dhabi (DOH). Dubai operators report to the Dubai Health Authority (DHA), while Northern Emirates providers are regulated by the Ministry of Health and Prevention (MOHAP). A cross-emirate post-acute model has to manage separate licensing, clinical governance and insurance approval processes across those regulators.

The operating gap is practical. Acute hospitals need discharge destinations for stroke, trauma, neurological rehabilitation and chronic ventilated patients. Insurers need lower-cost alternatives to prolonged acute admissions. Families need options between hospital wards and home care. Cambridge Health Group's 715-bed base gives Amanat more leverage with payers and referral hospitals than smaller standalone rehabilitation centres.

Medical directors should expect more scrutiny of outcomes data as Cambridge Health Group grows. Rehabilitation providers competing for tertiary referrals will need evidence on functional recovery, readmissions and length of stay. HR leaders should also track the 1,000-bed target because it implies demand for rehabilitation physicians, nurses, physiotherapists, occupational therapists and case managers across the UAE and Saudi Arabia.

The next signal is where Amanat puts capital after full control. If the next assets are in Abu Dhabi or Al Ain, DOH licensing and payer policy will shape the economics. If expansion moves into Dubai or the Northern Emirates, DHA and MOHAP approvals will determine how quickly beds can convert into revenue.